Exact Mass: 545.3352351999999

Exact Mass Matches: 545.3352351999999

Found 385 metabolites which its exact mass value is equals to given mass value 545.3352351999999, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Americine

N-[(10Z)-5,8-Dihydroxy-7-[(1H-indol-3-yl)methyl]-3-(propan-2-yl)-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-3-methyl-2-(methylamino)butanimidate

C31H39N5O4 (545.3001894)

Americine is found in tea. Americine is an alkaloid from the root bark of Ceanothus americanus (New Jersey tea Alkaloid from the root bark of Ceanothus americanus (New Jersey tea). Americine is found in tea.

LysoPC(20:3(5Z,8Z,11Z)/0:0)

(2-{[(2R)-2-hydroxy-3-[(5Z,8Z,11Z)-icosa-5,8,11-trienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C28H52NO7P (545.3481211999999)

LysoPC(20:3(5Z,8Z,11Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:3(5Z,8Z,11Z)), in particular, consists of one chain of mead acid at the C-1 position. The mead acid moiety is derived from fish oils, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

LysoPC(20:3(8Z,11Z,14Z)/0:0)

(2-{[(2R)-2-hydroxy-3-[(8Z,11Z,14Z)-icosa-8,11,14-trienoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C28H52NO7P (545.3481211999999)

LysoPC(20:3(8Z,11Z,14Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:3(8Z,11Z,14Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

Cholylhistidine

2-[(1-Hydroxy-4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-14-yl}pentylidene)amino]-3-(1H-imidazol-5-yl)propanoate

C30H47N3O6 (545.3464682)

Cholylhistidine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Cholylhistidine consists of the bile acid cholic acid conjugated to the amino acid Histidine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Cholylhistidine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Cholylhistidine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

12,13-epoxy-22S,25S,5alpha-veratranine-3beta,17,23alpha-triol-6-one N,O(3)-diacetate

C31H47NO7 (545.3352351999999)

panajaponin

C28H51NO9 (545.3563636)

gentiacraline

C32H39N3O5 (545.2889564)

Ergocornam

C31H39N5O4 (545.3001894)

Arg Gln Asp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-carboxypropanamido]hexanoic acid

C21H39N9O8 (545.2921454)

Asp Arg Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-5-carbamimidamidopentanamido]hexanamido]hexanoic acid

C22H43N9O7 (545.3285288)

Arg Ser Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]hexanamido]-5-carbamimidamidopentanoic acid

C21H43N11O6 (545.3397618)

Lys Asn Arg Glu

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]pentanamido]pentanedioic acid

C21H39N9O8 (545.2921454)

Lys Leu Gly Gln Ser

C23H43N7O8 (545.3172958)

Val Tyr His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C26H39N7O6 (545.2961674000001)

C28H52NO7P (545.3481211999999)

LPC(20:3)

1-Homo-gamma-linolenoyl-glycero-3-phosphocholine

C28H52NO7P (545.3481211999999)

PC(20:3(8Z,11Z,14Z)/0:0)

1-(8Z,11Z,14Z-eicosatrienoyl)-glycero-3-phosphocholine

C28H52NO7P (545.3481211999999)

LysoPC (20:3/0:0)

[(2R)-2-hydroxy-3-[(8Z,11Z,14Z)-icosa-8,11,14-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H52NO7P (545.3481212)

z-lys(aloc)-oh dcha

C30H47N3O6 (545.3464682)

Amyloid β-Protein (31-35)

C25H47N5O6S (545.3246882000001)

β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

TRIS(TRIETHOXYSILYLMETHYL)AMINE, tech-90

C21H51NO9Si3 (545.2871476)

adaprolol

C30H43NO8 (545.2988518000001)

Methylpendolmycin-14-O-alpha-glucoside

2-[[(4E,8E,12E)-2-acetamido-3-hydroxyhenicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C28H54N2O6P+ (545.3719294)

2-[[(4E,8E,12E)-2-(butanoylamino)-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C28H54N2O6P+ (545.3719294)

C32H39N3O5 (545.2889564)

n-[6-(2,6-dihydroxyhexyl)-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-(2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl)ethanimidic acid

C27H47NO10 (545.3199802)

(2s,4r,5r,6s,7s,9s)-4,6-dihydroxy-5,7-dimethyl-9-[(3r,7s,9s,10r,12r,13r)-5,7,9-trihydroxy-3,10,12-trimethyl-2-oxo-1-oxa-4-azacyclotridec-4-en-13-yl]decan-2-yl acetate

C28H51NO9 (545.3563636)

3-methyl-2-({[2,5,8-trihydroxy-6-isopropyl-3-(2-phenylethyl)-1,4,7-triazacyclotrideca-1,4,7-trien-9-yl]-c-hydroxycarbonimidoyl}amino)pentanoic acid

C28H43N5O6 (545.3213178000001)

(2s,4r,5s,6s,7s,9s)-2,6-dihydroxy-5,7-dimethyl-9-[(3r,7s,9s,10r,12r,13r)-5,7,9-trihydroxy-3,10,12-trimethyl-2-oxo-1-oxa-4-azacyclotridec-4-en-13-yl]decan-4-yl acetate

C28H51NO9 (545.3563636)

methyl (1r,9r,10s,12r,13e,18r)-4-[(4as,5r,6s)-5-ethenyl-1-oxo-3h,4h,4ah,5h,6h,7h-pyrano[3,4-c]pyridin-6-yl]-13-ethylidene-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

methyl (1r,9r,10s,12r,13e,18r)-4-[(4as,5r,6s)-5-ethenyl-1-oxo-3h,4h,4ah,5h,6h,7h-pyrano[3,4-c]pyridin-6-yl]-13-ethylidene-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

C32H39N3O5 (545.2889564)

(2s)-n-[(3s,4s,7s,10z)-5,8-dihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-3-methyl-2-(methylamino)butanimidic acid

C31H39N5O4 (545.3001894)

methyl (13z)-4-{5-ethenyl-1-oxo-3h,4h,4ah,5h,6h,7h-pyrano[3,4-c]pyridin-6-yl}-13-ethylidene-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

methyl (13z)-4-{5-ethenyl-1-oxo-3h,4h,4ah,5h,6h,7h-pyrano[3,4-c]pyridin-6-yl}-13-ethylidene-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

C32H39N3O5 (545.2889564)

(2s,3r,4s,5s,6r)-2-{[(10s,13s)-10-[(2s)-butan-2-yl]-11-hydroxy-9-methyl-5-(2-methylbut-3-en-2-yl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-13-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(10s,13s)-10-[(2s)-butan-2-yl]-11-hydroxy-9-methyl-5-(2-methylbut-3-en-2-yl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-13-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C29H43N3O7 (545.3100848)

n-[5,8-dihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,10,12,15-hexaen-4-yl]-3-methyl-2-(methylamino)butanimidic acid

C31H39N5O4 (545.3001894)

2-{[11-hydroxy-9-methyl-5-(2-methylbut-3-en-2-yl)-10-(sec-butyl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-13-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C29H43N3O7 (545.3100848)

(2r)-n-[(4s,4as,6r,8s,8ar)-6-[(2r)-2,6-dihydroxyhexyl]-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethanimidic acid

(2r)-n-[(4s,4as,6r,8s,8ar)-6-[(2r)-2,6-dihydroxyhexyl]-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethanimidic acid

5-[1-(1-acetyl-3-hydroxy-5-methylpiperidin-2-yl)ethyl]-5-hydroxy-6,11-dimethyl-17-oxo-7-oxapentacyclo[8.8.0.0²,⁸.0⁶,⁸.0¹¹,¹⁶]octadecan-14-yl acetate

C31H47NO7 (545.3352351999999)

[(1s,4r,5as,5br,7as,11as,11br,13r,13as)-13-(acetyloxy)-1,4-dimethoxy-5b,8,8,11a,13a-pentamethyl-3-oxo-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-2-yl]acetic acid

C31H47NO7 (545.3352351999999)

1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaen-20-yl}tridecan-2-one

C34H43NO5 (545.3141068)

7,9-dihydroxy-4,6-dimethyl-2-(5,7,9-trihydroxy-3,10,12-trimethyl-2-oxo-1-oxa-4-azacyclotridec-4-en-13-yl)decan-5-yl acetate

C28H51NO9 (545.3563636)

(2r)-n-[(4s,4ar,6r,8s,8ar)-6-[(2r)-2,6-dihydroxyhexyl]-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethanimidic acid

(2r)-n-[(4s,4ar,6r,8s,8ar)-6-[(2r)-2,6-dihydroxyhexyl]-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethanimidic acid

C27H47NO10 (545.3199802)

2,6-dihydroxy-5,7-dimethyl-9-(5,7,9-trihydroxy-3,10,12-trimethyl-2-oxo-1-oxa-4-azacyclotridec-4-en-13-yl)decan-4-yl acetate

C28H51NO9 (545.3563636)